Please login to the form below

Not currently logged in
Email:
Password:

Boehringer’s head of pharma heads for the exit

Comes amid restructuring and bolt-on deals to bolster business

BI

German drugmaker Boehringer Ingelheim is making changes at the top following the news that head of pharma Allan Hillgrove is retiring.

Hillgrove - a 37-year veteran at Boehringer - will step down by the end of the year and will be replaced by Carine Brouillon, who joined the company from Johnson & Johnson last year and is currently its head of prescription medicines.

Hillgrove

Allan Hillgrove

Company chairman Christian Boehringer said Hillgrove had made a significant contribution to the launch of new drugs like Ofev (nintedanib) for pulmonary fibrosis and diabetes therapy Jardiance (empagliflozin) and “thus the sustainable development of the company”.

Jardiance and Ofev are currently driving growth at the drugmaker, contributing almost €1.7bn to pharma revenues of €6.8bn in the first half of the year, and the company has also been particularly active of late in expanding it pipeline with bolt-on deals as it works through a business restructuring.

cb

Carine Bruillon

Recent deals have included a €325m acquisition of AMAL Therapeutics to gain access to its cancer vaccine technology, a $226m alliance with UK-listed biotech PureTech Health to develop a new approach to cancer immunotherapy, a €1.1bn licensing deal for an Ofev follow-up from Bridge Biotherapeutics, and an $870m tie-up with Yuhan for a non-alcoholic steatohepatitis (NASH) drug.

Brouillon will officially take over on 1 January 2020, taking over the responsibility of bedding in those new collaborations and spearheading new launches such as Ofev for systemic sclerosis.

The reshuffle is extending into other business units as well, with Joachim Hasenmaier - board member with responsibility for both animal and consumer health - stepping down after 18 years with the company.

Hasenmaier will also retire by the end of the year and will be succeeded as head of animal health by Jean Scheftsik de Szolnok, currently Boehringer’s animal health managing director in France.

28th August 2019

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics